Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4991MR)

This product GTTS-WQ4991MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4991MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11774MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ13036MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ9264MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ10373MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ3239MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ9822MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ8213MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ3659MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW